Income Statement

The income statement presents information on the financial results of a company business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.

Gilead Sciences Inc., consolidated income statement

US$ in millions

12 months ended:	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Product sales	28,610)	26,934)	26,982)	27,008)	24,355)
Cost of goods sold	(6,251)	(6,498)	(5,657)	(6,601)	(4,572)
Gross profit on product sales	22,359)	20,436)	21,325)	20,407)	19,783)
Royalty, contract and other revenues	144)	182)	299)	297)	334)
Research and development expenses	(5,907)	(5,718)	(4,977)	(5,363)	(5,039)
Acquired in-process research and development expenses	(4,663)	(1,155)	(944)	(177)	(5,856)
In-process research and development impairment	(4,180)	(50)	(2,700)	—)	—)
Selling, general and administrative expenses	(6,091)	(6,090)	(5,673)	(5,246)	(5,151)
Operating income	1,662)	7,605)	7,330)	9,918)	4,071)
Interest expense	(977)	(944)	(935)	(1,001)	(984)
Loss from equity securities, net	(274)	(167)	(657)	—)	—)
Interest income	281)	376)	106)	—)	—)
Other, net	(2)	(11)	(30)	(639)	(1,418)
Other income (expense), net	5)	198)	(581)	(639)	(1,418)
Income before income taxes	690)	6,859)	5,814)	8,278)	1,669)
Income tax expense	(210)	(1,246)	(1,248)	(2,077)	(1,580)
Net income	480)	5,613)	4,566)	6,201)	89)
Net loss attributable to noncontrolling interest	—)	52)	26)	24)	34)
Net income attributable to Gilead	480)	5,665)	4,592)	6,225)	123)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Download chart

Income statement item	Description	The company
Product sales	Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.	Gilead Sciences Inc. product sales decreased from 2022 to 2023 but then increased from 2023 to 2024 exceeding 2022 level.
Operating income	The net result for the period of deducting operating expenses from operating revenues.	Gilead Sciences Inc. operating income increased from 2022 to 2023 but then decreased significantly from 2023 to 2024.
Income before income taxes	Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.	Gilead Sciences Inc. income before income taxes increased from 2022 to 2023 but then decreased significantly from 2023 to 2024.
Net income attributable to Gilead	The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.	Gilead Sciences Inc. net income attributable to Gilead increased from 2022 to 2023 but then decreased significantly from 2023 to 2024.

Gilead Sciences Inc. (NASDAQ:GILD)

Income Statement